United States Cell and Gene Therapy Third-Party Logistics Market Report by Type, Product, Therapeutic Area, End Use, States and Company Analysis, 2026-2034

United States Cell and Gene Therapy Third-Party Logistics Market Size and Forecast 2026-2034

United States Cell and Gene Therapy Third-Party Logistics Market is expected to reach US$ 6.43 Billion by 2034 from US$ 2.85 Billion in 2025, with a CAGR of 9.46% from 2026 to 2034. Growing cell and gene therapy pipelines, increasing clinical trials, complex temperature-controlled logistics, personalized treatment models, and expanding biopharmaceutical manufacturing are driving demand for specialized third-party logistics providers across the United States.

United States Cell and Gene Therapy Third-Party Logistics Industry Overview

The United States cell and gene therapy third-party logistics industry is developing rapidly as advanced therapies move from research laboratories and clinical trials toward commercial treatment. Cell and gene therapies require logistics systems capable of managing highly sensitive biological materials, including patient-derived cells, viral vectors, genetically modified cells, and other temperature-sensitive products. Unlike conventional pharmaceuticals, many therapies involve time-critical movement between collection centers, manufacturing facilities, testing laboratories, hospitals, and treatment sites. Third-party logistics providers increasingly support transportation planning, specialized packaging, temperature monitoring, chain-of-identity management, inventory coordination, customs support, and shipment visibility. The expansion of personalized medicine and decentralized clinical research is creating additional requirements for reliable logistics infrastructure.

The market is also benefiting from increasing investment in biopharmaceutical research and the development of sophisticated manufacturing networks across the United States. Cell and gene therapy supply chains frequently require cryogenic or controlled-temperature transportation, validated packaging, real-time monitoring, and rapid intervention capabilities. Logistics providers are therefore developing specialized services rather than relying solely on conventional pharmaceutical distribution models. Integration of digital tracking technologies, automated shipment monitoring, electronic documentation, and advanced data platforms is improving supply-chain visibility. Providers are also strengthening capabilities around regulatory compliance, quality management, risk mitigation, and temperature excursion management. These capabilities are particularly important because a shipment delay or temperature deviation can compromise valuable biological material and potentially disrupt patient treatment.

Geographically, California, Texas, New York, and Florida represent important markets because of their pharmaceutical research ecosystems, biotechnology companies, clinical infrastructure, universities, hospitals, and specialized treatment centers. California benefits from major biotechnology clusters, while Massachusetts is also strategically important nationally because of its concentration of life-science companies and research institutions. Texas provides extensive healthcare infrastructure and growing biomanufacturing capabilities, whereas New York benefits from major academic medical centers and pharmaceutical research activity. Florida contributes through its healthcare and clinical-research ecosystem. Across the United States, the expansion of commercial cell and gene therapies is encouraging logistics companies to establish dedicated healthcare networks, validated packaging solutions, cryogenic transportation capabilities, and specialized handling procedures. Increasing therapy complexity, wider clinical adoption, and the need for reliable patient-to-manufacturer connectivity are expected to support continued demand for specialized third-party logistics services.

Growth Drivers for the United States Cell and Gene Therapy Third-Party Logistics Market

Expanding Cell and Gene Therapy Pipeline

The expanding pipeline of cell and gene therapies is creating increasingly complex logistics requirements throughout the United States. Developers are advancing therapies across oncology, rare diseases, genetic disorders, immunology, and other therapeutic areas, increasing the volume and geographic distribution of clinical and commercial shipments. Many products cannot be transported using conventional pharmaceutical distribution systems because their biological characteristics require highly controlled environmental conditions. Autologous cell therapies are particularly logistics-intensive because material may travel from an individual patient to a manufacturing facility and subsequently return to the treatment center. This creates a tightly coordinated circular supply chain involving collection, transportation, manufacturing, testing, storage, and administration. Third-party logistics providers can manage these interconnected activities while maintaining shipment visibility and documentation. As more therapies progress toward commercialization, pharmaceutical and biotechnology companies increasingly require logistics partners with specialized handling capabilities, validated packaging, temperature monitoring, and experience managing time-sensitive healthcare shipments.

Increasing Demand for Temperature-Controlled Logistics

Temperature-controlled logistics represents a major growth opportunity because many cell and gene therapy products require precise environmental conditions throughout transportation and storage. Depending on the therapy and manufacturing process, products may require refrigerated, frozen, ultra-low-temperature, or cryogenic conditions. Maintaining these conditions becomes particularly challenging when shipments move across multiple geographic locations or involve transfers between collection facilities, manufacturing sites, laboratories, and hospitals. Specialized third-party logistics companies provide validated packaging, temperature-monitoring devices, qualified transportation routes, contingency planning, and shipment visibility to minimize risks. Increasing adoption of cryogenic storage and transportation is also encouraging providers to invest in specialized containers and handling infrastructure. As therapy developers expand clinical trials and commercial distribution networks, demand for reliable cold-chain services is expected to increase. The ability to maintain product integrity while meeting strict delivery timelines makes specialized logistics providers increasingly important partners within advanced therapy supply chains.

Growth of Biopharmaceutical Manufacturing and Clinical Research

Increasing investment in biopharmaceutical manufacturing and clinical research is strengthening demand for specialized third-party logistics services in the United States. Cell and gene therapy development requires coordination among biotechnology companies, contract development and manufacturing organizations, hospitals, clinical trial sites, laboratories, and specialized treatment centers. As manufacturing networks become geographically distributed, transportation requirements become more complicated. Logistics providers can support manufacturers by coordinating inbound raw materials, clinical samples, finished therapies, returns, documentation, and time-sensitive deliveries. The expansion of decentralized and multicenter clinical trials further increases the number of locations requiring specialized logistics capabilities. Biopharmaceutical companies can outsource these activities to experienced providers rather than developing extensive internal transportation infrastructure. Third-party logistics companies can consequently become integrated into supply-chain planning, providing shipment visibility, temperature monitoring, inventory coordination, packaging management, and emergency transportation. Continued investment in advanced therapies is therefore expected to expand the addressable logistics opportunity.

Challenges in the United States Cell and Gene Therapy Third-Party Logistics Market

Complex Temperature-Control and Chain-of-Custody Requirements

Cell and gene therapy logistics involves considerably greater complexity than conventional pharmaceutical transportation because products can be extremely sensitive to temperature fluctuations, handling conditions, timing, and identification errors. Some therapies require frozen or cryogenic transportation, making validated packaging and specialized equipment essential. A temperature excursion can potentially damage or invalidate a shipment, resulting in substantial financial losses and treatment delays. Autologous therapies add another layer of complexity because patient-specific material must remain accurately identified throughout collection, manufacturing, transportation, and administration. Logistics providers therefore require robust chain-of-identity and chain-of-custody procedures, redundant monitoring systems, trained personnel, and contingency transportation plans. Maintaining these capabilities across multiple locations can increase operating costs. Smaller logistics providers may find the required investment in specialized infrastructure, technology, compliance systems, and personnel difficult. Consequently, operational complexity and quality requirements remain important barriers to broader participation in the market.

High Infrastructure and Compliance Costs

Specialized cell and gene therapy logistics requires substantial investment in infrastructure, technology, workforce training, validated packaging, temperature-monitoring systems, cryogenic equipment, and quality-management processes. Providers must also maintain compliance with pharmaceutical transportation requirements and customer-specific quality standards. Unlike conventional logistics, advanced therapy shipments often require detailed documentation, controlled handling procedures, secure data management, and continuous shipment visibility. These requirements increase the cost of establishing and maintaining specialized operations. Furthermore, unexpected transportation delays, weather disruptions, equipment failures, and route changes can create significant operational risks. Providers must maintain contingency capabilities to protect valuable shipments and meet strict delivery windows. Smaller third-party logistics companies may struggle to achieve the scale necessary to absorb these investments, encouraging consolidation and specialization within the industry. Balancing premium service capabilities with commercially competitive pricing therefore remains a persistent challenge for logistics providers serving cell and gene therapy customers.

California Cell and Gene Therapy Logistics Market - West Coast Innovation Hub

California represents one of the most important U.S. markets for cell and gene therapy third-party logistics because of its extensive biotechnology, pharmaceutical research, healthcare, and academic ecosystem. The state contains major biotechnology clusters around the San Francisco Bay Area, San Diego, and Los Angeles, generating demand for specialized transportation between laboratories, manufacturing facilities, clinical research organizations, hospitals, and treatment centers. The presence of advanced research institutions and biotechnology companies supports continued development of cell and gene therapies, while a large healthcare network provides potential administration sites. California's geographic scale also increases the need for reliable intra-state and inter-state transportation services. Logistics providers serving the region increasingly require temperature-controlled transportation, validated packaging, real-time shipment monitoring, and chain-of-identity management. The state's strong technology ecosystem can further encourage adoption of digital logistics platforms. Growing biotechnology investment and advanced-therapy development are expected to sustain demand for specialized third-party logistics capabilities.

Texas Cell and Gene Therapy Logistics Market - Expanding Healthcare and Biomanufacturing Base

Texas is emerging as an important market for cell and gene therapy third-party logistics due to its large healthcare infrastructure, biotechnology activity, research institutions, and growing biomanufacturing ecosystem. Major metropolitan areas including Houston, Dallas-Fort Worth, Austin, and San Antonio support hospitals, research centers, pharmaceutical organizations, and clinical facilities that require specialized transportation services. The state's geographic size creates demand for efficient connections between clinical sites, laboratories, manufacturing locations, and distribution facilities. Cell and gene therapy logistics providers can support these networks through controlled-temperature transportation, specialized packaging, shipment monitoring, and time-sensitive delivery management. Texas also benefits from significant medical research activity, particularly around major academic medical centers and cancer treatment institutions. As advanced therapies progress through clinical development and commercial deployment, logistics requirements are expected to become more sophisticated. Investment in healthcare infrastructure and biopharmaceutical manufacturing should consequently strengthen opportunities for specialized third-party logistics providers across Texas.

New York Cell and Gene Therapy Logistics Market - Dense Clinical Research Ecosystem

New York provides a significant opportunity for cell and gene therapy third-party logistics providers because of its concentration of pharmaceutical research, biotechnology companies, academic institutions, hospitals, and specialized treatment centers. New York City and surrounding areas contain major healthcare systems and research organizations that participate in advanced therapy development and clinical programs. This concentration creates recurring requirements for secure and time-sensitive transportation of biological materials, clinical samples, investigational products, and finished therapies. Logistics providers must accommodate demanding delivery schedules while maintaining appropriate temperature conditions and documentation. The state's dense urban environment also creates operational challenges involving traffic, delivery access, and scheduling, increasing the value of experienced healthcare logistics providers. Strong connectivity with other U.S. biotechnology centers further supports inter-state transportation requirements. As research institutions and biopharmaceutical companies continue developing personalized therapies, specialized logistics capabilities involving chain-of-custody, digital tracking, validated packaging, and rapid transportation are expected to become increasingly important.

Florida Cell and Gene Therapy Logistics Market - Healthcare and Clinical Expansion

Florida's cell and gene therapy third-party logistics market is supported by its expanding healthcare infrastructure, clinical research activity, biotechnology initiatives, and large network of hospitals and specialized medical facilities. Major metropolitan areas such as Miami, Orlando, Tampa, and Jacksonville contribute to demand for healthcare transportation and provide connections between clinical sites, laboratories, treatment centers, and pharmaceutical supply chains. The state's growing population and extensive healthcare ecosystem create opportunities for advanced therapies, while clinical research organizations can generate additional requirements for transporting investigational materials and biological samples. Specialized logistics providers must manage temperature-sensitive shipments, secure documentation, tracking, and strict delivery schedules. Florida's geographic position also supports connections with other U.S. markets and international supply chains. As advanced therapies become increasingly available outside traditional biotechnology hubs, Florida can benefit from expanding treatment networks. Investments in specialized cold-chain capabilities and digital shipment monitoring should further support market development.

Clinical Market - Supporting Time-Critical Therapy Development

Clinical applications represent a major logistics segment because cell and gene therapy development depends on coordinated movement of investigational products, patient-derived materials, biological samples, and supporting supplies between clinical trial locations and manufacturing facilities. Multicenter studies can involve hospitals, research centers, laboratories, and contract organizations across numerous geographic locations. Third-party logistics providers help coordinate these movements while maintaining temperature specifications, chain-of-custody records, shipment visibility, and delivery schedules. Autologous therapies require particularly precise coordination because patient material and manufactured treatment must remain correctly associated throughout the process. Clinical trials can also generate unpredictable shipment volumes and urgent transportation requirements, requiring logistics providers to maintain flexible capacity. As advanced therapies move through increasingly sophisticated clinical development programs, specialized logistics services can reduce operational complexity for biotechnology sponsors. Demand is therefore supported by growing clinical research activity, expanding trial networks, increasing biological sample movement, and the need for reliable time-critical transportation.

Cell Therapies - Specialized Patient-to-Manufacturer Transportation

Cell therapies create distinctive third-party logistics requirements because biological materials may need to move between patients, collection centers, manufacturing facilities, testing laboratories, storage locations, and treatment sites. Autologous therapies are particularly demanding because each patient's starting material and final treatment must remain accurately identified and coordinated throughout the supply chain. Logistics providers support these processes through controlled-temperature transportation, specialized packaging, chain-of-identity documentation, real-time monitoring, and scheduled delivery. Allogeneic cell therapies may offer greater manufacturing scalability but still require carefully controlled transportation and storage conditions. Increasing development of CAR-T therapies and other advanced cellular treatments is encouraging logistics companies to develop dedicated capabilities for handling sensitive biological products. Providers with validated infrastructure, trained personnel, contingency planning, and digital tracking systems can offer greater reliability to biopharmaceutical companies. As cell therapies expand beyond specialized research settings into broader clinical use, logistics requirements are expected to become more geographically distributed and operationally sophisticated.

Oncology - High-Value Therapies Demand Reliable Delivery

Oncology is an important application area for cell and gene therapy logistics because advanced therapies are increasingly being investigated and commercialized for cancers and hematological malignancies. CAR-T cell therapies and other genetically modified cellular treatments require highly coordinated movement between patient treatment centers, collection facilities, specialized manufacturing sites, laboratories, and storage locations. The high clinical value and individualized nature of these therapies increase the consequences of transportation delays, identification errors, or temperature excursions. Third-party logistics providers can support oncology supply chains through dedicated transportation, validated packaging, cryogenic capabilities, shipment tracking, and contingency management. The expansion of specialized cancer centers and broader availability of advanced oncology treatments can increase the number of locations participating in these supply chains. Logistics providers must consequently maintain reliable service across geographically dispersed networks. Increasing precision medicine adoption and continued investment in oncology research are expected to reinforce demand for specialized logistics solutions capable of managing highly sensitive and time-critical therapies.

Biopharmaceutical Companies - Outsourcing Drives Specialized Logistics Demand

Biopharmaceutical companies represent a core customer group for cell and gene therapy third-party logistics providers. Drug developers increasingly outsource transportation, packaging, warehousing, monitoring, and supply-chain coordination activities to specialized partners with validated healthcare infrastructure. This approach enables companies to access advanced logistics capabilities without developing extensive internal networks for cryogenic transportation, temperature monitoring, chain-of-custody management, and time-critical delivery. Large pharmaceutical organizations may require nationwide logistics coverage, while emerging biotechnology companies often depend more heavily on external providers because of limited internal resources. Contract manufacturing and distributed clinical networks further increase coordination requirements between developers, manufacturing organizations, laboratories, hospitals, and treatment centers. Third-party logistics providers can therefore become strategic partners rather than simple transportation vendors. Their ability to integrate digital tracking, quality management, regulatory documentation, specialized packaging, and contingency planning can improve supply-chain reliability. Continued biopharmaceutical investment in advanced therapies should support sustained outsourcing opportunities.

Frequently Asked Questions

1. What drives the United States cell and gene therapy third-party logistics market?

Growth is driven by expanding therapy pipelines, clinical trials, personalized medicine, temperature-controlled transportation requirements, biopharmaceutical outsourcing, and increasing commercialization of advanced therapies.

2. Why do cell and gene therapies require specialized logistics?

These therapies can require cryogenic or controlled-temperature transportation, strict chain-of-identity procedures, specialized packaging, real-time monitoring, and highly coordinated time-sensitive deliveries.

3. Which states are important for U.S. cell and gene therapy logistics?

California, Texas, New York, and Florida are significant markets because of their biotechnology, healthcare, clinical research, pharmaceutical, and advanced treatment infrastructure.

4. What role do third-party logistics providers play?

Providers manage transportation, packaging, temperature monitoring, shipment tracking, documentation, warehousing, chain-of-custody, contingency planning, and coordination among manufacturers and treatment facilities.

5. How does oncology influence logistics demand?

Oncology contributes significantly through CAR-T and other advanced therapies requiring secure, time-sensitive transportation between collection centers, manufacturing facilities, laboratories, and cancer treatment centers.

6. Why are biopharmaceutical companies outsourcing logistics?

Outsourcing provides access to specialized infrastructure, trained personnel, validated packaging, cold-chain capabilities, digital monitoring, and regulatory expertise without requiring companies to build extensive logistics networks.

7. What is the importance of cold-chain logistics?

Cold-chain logistics preserves the quality and integrity of temperature-sensitive therapies during transportation by maintaining specified environmental conditions and monitoring shipments throughout their journey.

Research Methodology of the United States Cell and Gene Therapy Third-Party Logistics Market

The United States Cell and Gene Therapy Third-Party Logistics Market was estimated using a structured bottom-up and top-down market-sizing methodology, supported entirely by secondary research, therapy shipment-volume analysis, logistics service pricing, cold-chain infrastructure assessment, company-level revenue analysis, and data triangulation. The methodology evaluated third-party logistics (3PL) services supporting the transportation, storage, handling, packaging, and distribution of cell and gene therapy products across the United States. The assessment covered temperature-controlled logistics, cryogenic transportation, ultra-low-temperature storage, specialized packaging, chain-of-identity and chain-of-custody management, real-time shipment monitoring, and time-critical delivery services. The estimate focused on revenue generated by external logistics providers specifically from supporting cell and gene therapy products.

1. Market Definition and Scope

• The market was defined by establishing the scope of third-party logistics services used for cell and gene therapy products.
• The assessment covered outsourced logistics activities required to maintain product quality, temperature integrity, traceability, and timely delivery throughout the therapy supply chain.
• The following service and product categories were considered:
• Cell therapy logistics: Transportation and storage of autologous and allogeneic cell therapies, including products derived from patient or donor cells.
• Gene therapy logistics: Specialized logistics for viral-vector-based and non-viral gene therapies.
• Temperature-controlled logistics: Refrigerated, frozen, ultra-low-temperature, and cryogenic transportation and storage.
• Packaging and handling: Validated thermal packaging, cryogenic containers, temperature-control systems, and specialized shipping materials.
• Shipment monitoring and traceability: Real-time temperature tracking, shipment visibility, chain-of-identity, and chain-of-custody management.
• Distribution services: Collection-site-to-manufacturing-site shipments, manufacturing-site-to-treatment-center deliveries, clinical trial logistics, and commercial distribution.
• The market included revenue earned by external logistics providers for services directly supporting cell and gene therapies.
• In-house logistics expenses were excluded unless the services were outsourced to a third-party provider.
• Pharmaceutical logistics unrelated to cell and gene therapy products were excluded.

2. Secondary Research and Data Collection

• Extensive secondary research was conducted to collect information on cell and gene therapy development, clinical trial activity, commercial product availability, shipment requirements, cold-chain infrastructure, and third-party logistics services in the United States.
• The following sources were reviewed:
• Government and regulatory agencies: U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), and relevant U.S. government publications.
• Clinical trial databases: ClinicalTrials.gov and other publicly available clinical research registries.
• Industry organizations: International Society for Cell & Gene Therapy (ISCT), Parenteral Drug Association (PDA), and relevant biopharmaceutical logistics associations.
• Company disclosures: Annual reports, investor presentations, service portfolios, press releases, and commercial announcements from specialized logistics providers.
• Therapy developer information: Public disclosures from cell and gene therapy manufacturers concerning clinical pipelines, commercial launches, manufacturing networks, and distribution requirements.
• Logistics and cold-chain publications: Information on cryogenic transportation, temperature-controlled warehousing, specialized packaging, and pharmaceutical supply-chain services.
• The collected information was used to estimate shipment volumes, storage requirements, outsourced logistics adoption, average service pricing, and revenue generated by logistics providers.

3. Cell and Gene Therapy Product and Pipeline Assessment

• The U.S. cell and gene therapy landscape was analyzed to establish the number of products requiring specialized logistics services.
• The assessment considered commercially marketed therapies, clinical-stage products, and investigational therapies requiring transportation between collection centers, manufacturing facilities, testing laboratories, and clinical sites.
• The following categories were examined:
• Approved and commercially available cell therapies.
• Approved gene therapies.
• Autologous cell therapies requiring patient-specific collection and delivery.
• Allogeneic cell therapies manufactured in batches for multiple patients.
• Clinical-stage cell and gene therapy candidates.
• Viral vectors and other specialized materials, where their logistics services fell within the defined market scope.
• Products were assessed according to their development stage, commercial availability, manufacturing location, treatment-center network, and logistics requirements.
• Clinical-stage products were included only to the extent that third-party logistics services were actually being purchased.

4. Shipment Volume Estimation

• The annual number of cell and gene therapy shipments handled by third-party logistics providers was estimated by assessing product volumes, clinical trial activity, commercial treatment demand, manufacturing requirements, and the number of shipment movements required across the supply chain.
• Autologous and allogeneic therapies were assessed separately because their logistics patterns differed.
• Autologous therapies were evaluated based on patient-specific collection, transportation to manufacturing facilities, return transportation, and coordinated delivery to treatment centers.
• Allogeneic therapies were evaluated based on batch manufacturing, inventory storage, and distribution to multiple treatment centers.
• The following shipment categories were considered:
• Collection-site-to-manufacturing-site shipments.
• Manufacturing-site-to-treatment-center shipments.
• Clinical trial material shipments.
• Viral vector and specialized raw-material shipments, where included in scope.
• Temperature-controlled transfers between storage and distribution facilities.
• Other outsourced shipment movements directly associated with cell and gene therapies.
• The following formulas were applied:
• Annual Therapy-Related Shipment Volume = Number of Eligible Patients or Treatment Batches X Average Shipment Movements per Patient or Batch.
• Outsourced Shipment Volume = Total Eligible Shipment Volume X Third-Party Logistics Adoption Rate.
• Commercial Therapy Shipment Volume = Annual Treatment Volume X Average Logistics Shipments per Treatment.
• Clinical Trial Shipment Volume = Relevant Clinical Trial Activity X Average Shipments per Trial or Patient.
• The calculations were adjusted to avoid counting the same shipment multiple times when it passed through several logistics stages.

5. Logistics Service Segmentation

• The market was segmented by logistics service to estimate the revenue contribution of each major service category.
• The assessment covered:
• Transportation: Domestic road, air, and specialized courier transportation.
• Cold-chain storage: Refrigerated, frozen, ultra-low-temperature, and cryogenic storage.
• Packaging services: Validated thermal packaging, cryogenic containers, packaging preparation, and specialized shipping materials.
• Monitoring and tracking: Temperature monitoring, shipment visibility, and exception management.
• Chain-of-identity and chain-of-custody services: Documentation and traceability systems supporting patient-specific products.
• Customs and regulatory coordination: Relevant documentation and handling services for shipments crossing international borders, where these services formed part of U.S.-related logistics revenue.
• Each service category was assessed according to utilization, service pricing, shipment requirements, and the extent to which therapy developers outsourced the activity.
• The following formulas were applied:
• Transportation Revenue = Annual Outsourced Shipments × Average Transportation Revenue per Shipment.
• Storage Revenue = Average Storage Volume Utilized × Average Storage Revenue per Unit.
• Packaging Revenue = Number of Shipments Requiring Specialized Packaging × Average Packaging Revenue per Shipment.
• Monitoring Revenue = Number of Monitored Shipments × Average Monitoring Revenue per Shipment.
• Service-Level Market Size = Sum of Revenue Across Relevant Logistics Service Categories.
• Where multiple services were bundled into a single contract, revenue was allocated across categories only when sufficient information was available. Otherwise, the contract was counted once within the appropriate combined service category.

6. Average Logistics Pricing Analysis

• Average logistics service pricing was estimated by evaluating the costs associated with specialized transportation, cryogenic handling, storage, validated packaging, monitoring, and time-critical delivery.
• Pricing was assessed separately for different shipment types because costs varied according to temperature requirements, distance, shipment urgency, packaging complexity, and handling procedures.
• The following factors were examined:
• Domestic transportation distance and delivery mode.
• Refrigerated, frozen, ultra-low-temperature, or cryogenic requirements.
• Shipment urgency and delivery time windows.
• Specialized packaging and container rental requirements.
• Temperature-monitoring and tracking services.
• Shipment size, weight, and handling complexity.
• Storage duration and capacity requirements.
• Contractual pricing and bundled logistics arrangements.
• The following formulas were applied:
• Average Revenue per Shipment = Total Relevant Logistics Revenue ÷ Number of Outsourced Shipments.
• Average Storage Revenue per Unit = Total Storage Revenue ÷ Average Storage Units Utilized.
• Average Revenue per Service Category = Total Service Category Revenue ÷ Number of Relevant Service Transactions.
• Where direct prices were unavailable, estimates were developed using publicly available service information, comparable specialized pharmaceutical logistics services, and company disclosures.

7. Cold-Chain and Cryogenic Infrastructure Assessment

• The availability and utilization of specialized logistics infrastructure were evaluated to understand the capacity required to support cell and gene therapy products in the United States.
• The assessment considered:
• Cryogenic storage facilities and liquid-nitrogen-based systems.
• Ultra-low-temperature freezers and storage environments.
• Validated cold-chain packaging and shipping containers.
• Temperature-controlled vehicles and air-freight arrangements.
• Temperature-monitoring devices and shipment tracking platforms.
• Specialized handling capabilities at manufacturing facilities, logistics hubs, and treatment centers.
• Infrastructure was assessed in terms of capacity, utilization, geographic coverage, service availability, and the proportion operated by third-party logistics providers.
• The following formulas were applied:
• Utilized Storage Capacity = Available Storage Capacity × Storage Utilization Rate.
• Annual Storage Revenue = Average Utilized Storage Capacity × Average Revenue per Storage Unit.
• Specialized Shipment Capacity = Available Qualified Shipping Units × Average Annual Shipment Turns per Unit.
• Infrastructure capacity was used as a validation measure rather than being treated directly as market revenue.

8. Autologous and Allogeneic Therapy Logistics Analysis

• The market was separately assessed for autologous and allogeneic therapies because their supply-chain structures and logistics costs differed.
• Autologous therapy logistics were evaluated based on patient-specific collection, transportation to manufacturing facilities, manufacturing turnaround requirements, return shipment coordination, and chain-of-identity controls.
• The analysis considered the number of patients treated, shipments per treatment, and the proportion of logistics activities outsourced.
• Allogeneic therapy logistics were assessed based on batch manufacturing, storage of inventory, distribution to multiple treatment centers, and shipment requirements associated with commercial and clinical supply.
• The following formulas were applied:
• Autologous Logistics Revenue = Number of Autologous Treatments × Average Outsourced Logistics Revenue per Treatment.
• Allogeneic Logistics Revenue = Number of Relevant Batches or Deliveries × Average Logistics Revenue per Batch or Delivery.
• Therapy-Type Market Size = Autologous Logistics Revenue + Allogeneic Logistics Revenue.
• Where a treatment required multiple logistics movements, the calculation included the relevant shipment stages while avoiding double counting of bundled services.

9. Clinical Trial and Commercial Logistics Analysis

• The market was divided between clinical trial logistics and commercial logistics to account for differences in shipment frequency, delivery requirements, and service utilization.
• Clinical trial logistics included transportation of investigational therapies, clinical materials, patient-specific products, and related temperature-sensitive shipments between collection sites, manufacturing locations, testing facilities, and clinical trial centers.
• Commercial logistics covered services supporting the distribution of marketed cell and gene therapies to authorized treatment facilities and other relevant delivery locations.
• The assessment considered the number of active clinical programs, trial locations, enrolled patients, commercially treated patients, and logistics requirements associated with each product.
• The following formulas were applied:
• Clinical Trial Logistics Revenue = Annual Clinical Trial Shipments × Average Revenue per Clinical Shipment.
• Commercial Logistics Revenue = Annual Commercial Shipments × Average Revenue per Commercial Shipment.
• Clinical and Commercial Market Size = Clinical Trial Logistics Revenue + Commercial Logistics Revenue.
• Only logistics activities that generated third-party service revenue were included.

10. Company-Level Revenue Analysis

• Revenue generated by third-party logistics providers operating in the U.S. cell and gene therapy market was assessed using annual reports, investor presentations, service descriptions, and company announcements.
• The analysis considered general pharmaceutical logistics providers as well as specialized cold-chain and advanced-therapy logistics companies.
• Company-level research focused on:
• Revenue from cell and gene therapy logistics services.
• Transportation and cryogenic shipping capabilities.
• Specialized packaging and storage services.
• Clinical trial logistics contracts.
• Commercial distribution agreements.
• Investments in cold-chain infrastructure and advanced-therapy capabilities.
• Partnerships with cell and gene therapy developers and manufacturers.
• When companies reported broader pharmaceutical logistics revenue, only the portion attributable to cell and gene therapy logistics was included.
• Product-specific contracts, disclosed capabilities, shipment estimates, and relevant commercial information were used to derive estimates where direct revenue figures were unavailable.

11. Bottom-Up Market Size Calculation

• The bottom-up approach was used to estimate market size by calculating revenue across individual logistics services, shipment categories, and therapy types.
• Transportation, storage, packaging, monitoring, and other relevant logistics revenues were estimated separately before being consolidated into the total market.
• The following formulas were applied:
• Transportation Market Size = Annual Outsourced Shipments × Average Transportation Revenue per Shipment.
• Storage Market Size = Average Utilized Storage Capacity × Average Storage Revenue per Unit.
• Packaging Market Size = Number of Specialized Packaging Transactions × Average Revenue per Transaction.
• Bottom-Up Market Size = Sum of Revenue Across Relevant Third-Party Logistics Services.
• The estimates were reconciled with company-level disclosures and adjusted to remove duplicate revenue arising from bundled services or multiple handling stages within the same logistics contract.

12. Top-Down Market Estimation

• A top-down approach was used to validate the bottom-up estimate by evaluating broader pharmaceutical logistics, cold-chain logistics, and specialized biopharmaceutical logistics revenues in the United States.
• The relevant portion attributable to cell and gene therapy products was estimated using the therapy pipeline, commercial product availability, shipment requirements, temperature-control complexity, and the share of logistics services outsourced to third-party providers.
• The following formulas were applied:
• Top-Down Market Size = Relevant U.S. Pharmaceutical Logistics Market Revenue × Cell and Gene Therapy Logistics Share.
• Outsourced Logistics Revenue = Eligible Cell and Gene Therapy Logistics Expenditure × Third-Party Outsourcing Rate.
• The top-down estimate was compared with shipment-based calculations and company-level revenue analysis.
• Differences were reviewed to identify inconsistencies in market coverage, service pricing, or outsourcing assumptions.

13. End-User and Customer Analysis

• The market was assessed by customer group to determine which organizations generated demand for outsourced cell and gene therapy logistics services.
• The analysis considered:
• Cell therapy developers.
• Gene therapy developers.
• Biopharmaceutical manufacturers.
• Contract development and manufacturing organizations (CDMOs).
• Clinical research organizations and trial sponsors.
• Hospitals and specialized treatment centers, where they directly purchased logistics services.
• Other organizations involved in the cell and gene therapy supply chain.
• Each customer category was evaluated according to the number of relevant products or clinical programs, shipment requirements, outsourcing practices, and logistics expenditure.
• The following formulas were applied:
• Customer-Group Market Size = Number of Relevant Customers × Average Annual Third-Party Logistics Spending per Customer.
• Customer-Group Market Share (%) = (Customer-Group Logistics Revenue ÷ Total Market Revenue) × 100.
• Revenue was allocated according to the organization purchasing the logistics service, rather than counting the same service again at the receiving facility.

14. Regulatory and Quality Compliance Assessment

• The regulatory and quality environment was examined to understand its influence on service requirements, operating costs, and market adoption.
• The assessment reviewed applicable FDA requirements, relevant good manufacturing practice considerations, shipping validation practices, temperature-control procedures, product traceability, and handling protocols.
• The analysis considered:
• Temperature-control and product-integrity requirements.
• Validated packaging and shipping procedures.
• Chain-of-identity and chain-of-custody controls.
• Shipment documentation and traceability.
• Quality-management requirements for logistics partners.
• Handling procedures for sensitive biological materials.
• The influence of compliance requirements on logistics pricing and provider selection.
• These factors were used to assess demand for specialized logistics services and differences in service pricing.
• Regulatory compliance costs were not added separately when they were already reflected in the logistics provider's service revenue.

15. Competitive Landscape and Market Share Analysis

• The competitive landscape was evaluated to identify leading logistics providers serving cell and gene therapy developers and manufacturers in the United States.
• Companies were compared based on service portfolios, cold-chain capabilities, cryogenic handling expertise, geographic coverage, customer relationships, and reported or estimated relevant revenue.
• The analysis also reviewed strategic partnerships, facility expansions, specialized service launches, and investments in advanced-therapy logistics infrastructure.
• The following formula was applied:
• Company Market Share (%) = (Company U.S. Cell and Gene Therapy Logistics Revenue ÷ Total U.S. Cell and Gene Therapy Third-Party Logistics Market Revenue) × 100.
• For companies operating across multiple pharmaceutical logistics segments, only revenue attributable to cell and gene therapy logistics was included in the market-share calculation.

16. Historical Data Analysis and Forecasting

• Historical trends were analyzed to establish a baseline for forecasting the U.S. cell and gene therapy third-party logistics market.
• The forecast incorporated anticipated changes in therapy approvals, clinical trial activity, patient treatment volumes, shipment complexity, outsourcing rates, and demand for specialized cold-chain services.
• The following factors were considered:
• Growth in commercially available cell and gene therapies.
• Expansion of clinical trial pipelines.
• Changes in patient treatment volumes and manufacturing output.
• Increasing requirements for cryogenic transportation and storage.
• Adoption of specialized packaging and digital shipment monitoring.
• Expansion of treatment-center and manufacturing networks.
• Changes in average logistics service pricing.
• Growth in outsourced logistics adoption.
• The following formulas were applied:
• Forecast Shipment Volume = Base-Year Shipment Volume × (1 + Annual Shipment Volume Growth Rate)ⁿ.
• Forecast Revenue per Shipment = Base-Year Revenue per Shipment × (1 + Annual Pricing Growth Rate)ⁿ.
• Forecast Market Size = Sum of (Forecast Service Volume × Forecast Revenue per Service Unit).
• Market Growth Rate (%) = [(Current-Year Market Size - Previous-Year Market Size) ÷ Previous-Year Market Size] × 100.
• Compound Annual Growth Rate (CAGR) = [(Ending Market Size ÷ Beginning Market Size)^(1 ÷ Number of Years) - 1] × 100.
• Separate assumptions were applied to transportation, storage, packaging, and monitoring services where their growth patterns differed.
• Forecasts were validated against expected therapy commercialization, clinical development activity, infrastructure expansion, and logistics outsourcing trends.

17. Data Triangulation and Validation

• The final market estimate was validated by comparing the bottom-up calculation, top-down assessment, shipment-volume analysis, infrastructure utilization, and company-level revenue estimates.
• The validation process included:
• Comparing estimated shipment volumes with clinical and commercial therapy activity.
• Reconciling logistics revenue estimates with company disclosures.
• Reviewing average service pricing and outsourcing assumptions.
• Checking for duplication across transportation, storage, packaging, and monitoring services.
• Comparing estimated storage utilization with available specialized infrastructure.
• Reviewing historical trends and forecast assumptions.
• Refining estimates where independent sources indicated material differences.
• Only revenue attributable to third-party logistics services supporting cell and gene therapy products in the United States was included in the final market calculation.

18. Final Market Size Estimation

• The final U.S. cell and gene therapy third-party logistics market size was calculated by consolidating validated revenue estimates across transportation, storage, packaging, shipment monitoring, and other relevant outsourced logistics services.
• The final estimate incorporated:
• Shipment volumes and average service pricing.
• Therapy type and clinical or commercial activity.
• Customer outsourcing practices.
• Company-level revenue validation.
• Adjustments for duplicate revenue arising from bundled services or overlapping supply-chain stages.
• The resulting market value represented the estimated annual revenue generated by third-party logistics providers supporting cell and gene therapy products in the United States during the selected base year.
• The same methodology was applied to subsequent forecast years, with adjustments for changes in therapy volumes, product commercialization, shipment requirements, service pricing, and outsourcing adoption.

Market Segmentations

Type

• Clinical
• Commercial

Product

• Cell Therapies
• Gene Therapies

Therapeutic Area

• Oncology
• Neurology
• Cardiovascular Diseases
• Ophthalmology
• Infectious Diseases
• Others

End Use

• Biopharmaceutical Companies
• CDMOs/CMOs
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Cencora Corporation
• Cardinal Health
• McKesson Corporation
• EVERSANA
• Knipper Health
• Arvato SE
• DHL
• Kuehne+Nagel